Use of nutritional composition for non-therapeutic purposes of improving vision

Abstract

The present invention relates to the use of a nutritional composition comprising medium and long chain fatty acid triglycerides and nervonic acids for non-therapeutic purposes of improving vision.

Description

Technical Field

[0001] The present invention relates to the field of food and medicine, and specifically to the use of a nutritional composition comprising medium-chain and long-chain fatty acid triglycerides and neuraminic acid for the non-therapeutic purpose of improving vision, and the use of the nutritional composition in the preparation of medicines for improving vision. Background Art

[0002] In recent years, vision problems have increasingly aroused people's concerns and attention around the world, and are also developing towards a trend of popularization and younger people. At the same time, with the rapid popularization of electronic devices such as mobile phones, televisions, and computers in people's lives, visual fatigue caused by improper and excessive use of eyes is also becoming a major problem that troubles people. For example, these electronic devices emit blue light, and long-term exposure to blue light is not only easy to cause visual fatigue, but also causes blue light damage to the retina, leading to a series of eye diseases such as light damage. Myopia and visual fatigue have attracted widespread attention.

[0003] In view of the above problems, it is of great significance to develop methods that can effectively protect eyesight, such as relieving visual fatigue and preventing myopia. Summary of the invention

[0004] The present invention is made in view of the above problems existing in the prior art.

[0005] The present invention relates to the use of a nutritional composition for the non-therapeutic purpose of improving vision. The nutritional composition comprises: medium- and long-chain triacylglycerol (MLCT); and nervonic acid (NA, nervonic acid, also known as cis-15-tetracosenoic acid).

[0006] The present invention also relates to the use of the nutritional composition in preparing medicines for improving vision.

[0007] The inventors unexpectedly discovered in their research that when medium-chain fatty acid triglycerides and neuraminic acid are used in combination, they exhibit a synergistic effect in protecting vision, especially in relieving visual fatigue (e.g., anti-blue light) and optionally in preventing myopia. The effect of their combined use is better than the effect of the same total amount of medium-chain fatty acid triglycerides alone, and also better than the effect of the same total amount of neuraminic acid alone. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] In order to more clearly illustrate the technical solution of the present invention, the following will briefly describe the drawings required for describing the embodiments. It should be understood that these drawings are only for the convenience of technicians to understand the present invention more easily, and are not intended to limit the scope of the present invention.

[0009] Figure 1The photographs show the fluorescence intensity of apoptotic cells in the eyes of zebrafish in the normal control group, the model control group, the positive control group using coenzyme Q10, and the experimental groups using medium-chain triglycerides (MLCT) or neuraminic acid alone.

[0010] Figure 2 The fluorescence intensity of apoptotic cells in the eyes of zebrafish in the normal control group, model control group, positive control group using coenzyme Q10, and experimental groups using medium- and long-chain fatty acid triglycerides or neuraminic acid alone are presented, and the statistical analysis results compared with the model control group are as follows: Denotes p < 0.001.

[0011] Figure 3 The photographs show the fluorescence intensity of apoptotic cells in the eyes of zebrafish in the normal control group, the model control group, the positive control group using coenzyme Q10, the experimental group using medium-chain triglycerides (MLCT) or neuraminic acid alone, and the experimental group using medium-chain triglycerides and neuraminic acid in combination.

[0012] Figure 4 The photographs show the retinal pigment epithelium diameter / sclera diameter of zebrafish in the normal control group, model control group, MO standard control group, positive control group using atropine, and experimental groups using medium-chain triglycerides (MLCT) or neuraminic acid alone.

[0013] Figure 5 The retinal pigment epithelium diameter / sclera diameter of zebrafish in the normal control group, model control group, MO standard control group, positive control group using atropine, and experimental groups using medium- and long-chain fatty acid triglycerides or neuraminic acid alone, as well as the statistical analysis results compared with the model control group, are presented: indicates p < 0.05, indicates p < 0.01, Denotes p < 0.001.

[0014] Figure 6 The photographs are presented to show the retinal pigment epithelium diameter / sclera diameter of zebrafish in the normal control group, model control group, MO standard control group, positive control group using atropine, experimental groups using medium-chain triglycerides (MLCT) or neuraminic acid alone, and experimental groups using medium-chain triglycerides and neuraminic acid in combination. DETAILED DESCRIPTION

[0015] In order to make the invention purpose, technical solution and beneficial technical effect of the present application clearer, the present application will be described in detail below. It should be noted that the various aspects, features, implementation methods and advantages described in the present application may be compatible and / or may be combined together.

[0016] Unless otherwise specified, the meanings of the technical terms or scientific terms in this specification are the same as those generally understood by those skilled in the art.

[0017] In the present application, unless otherwise specified, the temperature is room temperature (25° C.), the atmosphere is air, and the pressure is atmospheric pressure.

[0018] In the present application, the term "medium-chain fatty acid" refers to fatty acids with 6-12 carbon atoms in the carbon chain, such as caproic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc.; the term "long-chain fatty acid" refers to fatty acids with more than 14 carbon atoms, generally 14-30 carbon atoms, in the carbon chain, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, etc. The terms "medium-chain fatty acid triglyceride" and "long-chain fatty acid triglyceride" refer to the esterification reaction products of "medium-chain fatty acid" and "long-chain fatty acid" with glycerol, respectively; the term "medium-long chain fatty acid triglyceride" refers to triglycerides containing both medium-chain fatty acid residues and long-chain fatty acid residues in the molecular structure.

[0019] In this application, "special food" refers to special types of food for specific groups of people, such as "the elderly, the young, and the sick", including three categories: health food, infant formula, and special medical purpose formula food.

[0020] The present invention relates to the use of a nutritional composition comprising medium-chain and long-chain fatty acid triglycerides and nervonic acid for the non-therapeutic purpose of improving vision, and the use of the nutritional composition in the preparation of a medicine for improving vision.

[0021] Among the components contained in the nutritional composition of the present invention, neuraminic acid (cis-15-tetracosenoic acid, abbreviated as NA) is an essential high-level nutrient for the growth, redevelopment and function maintenance of nerve cells, especially brain cells and peripheral nerve cells.

[0022] In addition, medium-chain triglycerides (MLCTs) are structural lipids that contain both medium-chain fatty acids and long-chain fatty acids in triglyceride molecules, and have different physical and chemical properties, metabolic characteristics, and nutritional values ​​from long-chain triglycerides or medium-chain triglycerides. Studies (see, for example, Yuan Tinglan, Composition of medium-chain triglycerides in breast milk fat and its metabolic characteristics [D], Jiangnan University, 2021) show that medium-chain triglycerides are not simply equivalent to a physical mixture of long-chain triglycerides and medium-chain triglycerides (of course, they are not equivalent to a simple mixture of long-chain fatty acids and medium-chain fatty acids), and the latter do not have the physical and chemical properties, metabolic characteristics, and nutritional value of the former.

[0023] The inventors unexpectedly discovered in their research that when medium-chain fatty acid triglycerides and neuraminic acid are used in combination, they exhibit a synergistic effect in protecting vision, especially in relieving visual fatigue (e.g., anti-blue light) and optionally in preventing myopia. The effect of their combined use is better than the effect of the same total amount of medium-chain fatty acid triglycerides alone, and also better than the effect of the same total amount of neuraminic acid alone.

[0024] The nervonic acid used in the present invention can be derived from biological sources or artificially synthesized. For example, nervonic acid can be derived from shark brain, M. adenantha, garlic fruit, Xanthoceras sorbifolia, Acer truncatum seeds, fungi such as filamentous fungi M. phaseoline, yeast S. cerevisiae, etc., or artificially synthesized using 9-docosahexaenoic acid and propionic acid ester as raw materials, artificially synthesized using oleic acid and suberate as raw materials, etc. The nervonic acid can be used in pure form or in a non-pure form rich in nervonic acid.

[0025] The present invention has no special requirements for the medium-chain triglycerides used, and the medium-chain triglycerides commonly used in the art can be used. The medium-chain triglycerides can be used in pure form or in an impure form rich in medium-chain triglycerides.

[0026] In some embodiments, the medium-chain fatty acid triglycerides used in the present invention include C6-C 12 Fatty acid residues and C 14 -C 30 Fatty acid residues, wherein: the C6-C 12 The fatty acid residue is derived from one or more of the following: caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, dodecanoic acid (or lauric acid), etc., preferably caproic acid, caprylic acid, capric acid and lauric acid; and / or the C 14 -C 30 The fatty acid residue is derived from one or more of the following: myristic acid, palmitic acid, heptadecanoic acid, oleic acid, linoleic acid, stearic acid, nonadecanoic acid, eicosapentaenoic acid, heneicosanoic acid, docosatetraenoic acid, docosahexaenoic acid, tricosanoic acid, tetracosenoic acid, eicosapentaenoic acid, hexacoshexaenoic acid, arachidonic acid, etc., preferably myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid.

[0027] In some embodiments, the C6-C 12 The fatty acid residues on the C 14 -C 30 The weight ratio of fatty acid residues is 0.124 to 2.000. As an example, the C6-C 12 The fatty acid residues on the C 14-C 30 The weight ratio of the fatty acid residues may be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, or within the range defined by any two of them.

[0028] In some embodiments, in the nutritional composition defined herein, the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is 1:1 to 550:1. When the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is within the above range, the synergistic effect of nervonic acid and medium-chain fatty acid triglyceride in improving vision, especially relieving visual fatigue (e.g., anti-blue light) is more significant. As an example, the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid may be 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2:1, 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 3:1, 4:1, 5:1, 6:1 、7:1、8:1、9:1、10:1、11:1、12:1、13:1、14:1、15:1、20:1、25:1、30:1、35:1、40:1、45:1、50:1、55:1、60:1、65:1、70:1、75:1、76:1、78:1、80:1、90:1、100:1、120:1、13 0:1、140:1、150:1、160:1、170:1、180:1、190:1、200:1、210:1、220:1、230:1、240:1、250:1、260:1、270:1、280:1、290:1、300:1、310:1、320:1、330:1、340:1、350:1、 360:1, 370:1, 380:1, 390:1, 400:1, 410:1, 420:1, 430:1, 440:1, 450:1, 460:1, 470:1, 480:1, 490:1, 500:1, 510:1, 520:1, 530:1, 540:1, 550:1, or the range defined by any two of them. Preferably, the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is 1:1 to 350:1; when the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is within this range, the synergistic effect of nervonic acid and medium-chain fatty acid triglyceride in improving vision, especially relieving visual fatigue (e.g., anti-blue light) is more obvious. More preferably, the weight ratio of the medium-chain fatty acid triglycerides to the neuraminic acid is 2:1 to 200:1; when the weight ratio of the medium-chain fatty acid triglycerides to the neuraminic acid is within this range, the synergistic effect of neuraminic acid and medium-chain fatty acid triglycerides in relieving visual fatigue (such as anti-blue light) and preventing myopia is more significant.More preferably, the weight ratio of the medium-chain fatty acid triglycerides to the neuraminic acid is 2:1 to 80:1; when the weight ratio of the medium-chain fatty acid triglycerides to the neuraminic acid is within this range, the synergistic effect of neuraminic acid and medium-chain fatty acid triglycerides in relieving visual fatigue (such as anti-blue light) and preventing myopia is more obvious.

[0029] In some embodiments, alleviating eyestrain comprises protecting against blue light.

[0030] In some embodiments, the nutritional composition defined herein may consist of medium and long chain fatty acid triglycerides and nervonic acid.

[0031] In some embodiments, the nutritional composition is used in the form of a food comprising the nutritional composition. In some embodiments, the food is an infant food such as an infant formula.

[0032] In some embodiments, the food is a common food or a special food. As an example, the food can be selected from dairy products, candies, beverages, bread and biscuits, for example, the food can be selected from milk powder or fermented food. In some embodiments, the milk powder is infant formula milk powder.

[0033] In some embodiments, based on the dry weight of the food, the content of neuraminic acid may be 0.001% to 1.5%, for example, 0.001% to 1%, and the content of medium- and long-chain fatty acid triglycerides may be calculated according to the ratio of the two. As an example, based on the weight of the food, the content of neuraminic acid may be 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.008, 0.010, 0.015, 0.020, 0.030, 0.040, 0.050, 0.052, 0.060, 0.070, 0.080, 0.090, 0.10, 0.20, 0.30, 0.40, 0.45, 0.50, 0.55, 0.60, 0.70, 0.80, 0.90, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 weight %, or within the range defined by any two of them.

[0034] In some embodiments, based on the dry basis weight of the food, the content of medium and long-chain fatty acid triglycerides can be 0.1% to 30.0%. As an example, based on the weight of the food, the content of medium and long-chain fatty acid triglycerides can be 0.1, 0.2, 0.5, 0.8, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0 weight %, or any two of them in the range defined.

[0035] In addition, it is easy for those skilled in the art to understand that, in addition to the nutritional composition of the first aspect of the present invention, the food also includes one or more selected from the following: raw milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blending oil, oligofructose, oligogalactose, nucleotides, choline, vitamins, minerals, DHA and taurine.

[0036] For example, when the food is milk powder, in addition to the nutritional composition described in the first aspect of the present invention, the milk powder may also include proteins such as α-lactalbumin and milk fat globule membrane protein; carbohydrates such as lactose; lipids; minerals such as calcium, iron, phosphorus, etc.; vitamins; other additives such as whey powder, choline bitartrate, docosahexaenoic acid, arachidonic acid, walnut oil, etc.

[0037] The food can be produced by a preparation method commonly used in the art, which will not be described in detail here.

[0038] In a first embodiment, the improved vision may include relieving visual fatigue, such as anti-blue light, and optionally further includes preventing myopia. As previously mentioned, when the weight ratio of the medium- and long-chain fatty acid triglycerides to the nervonic acid is within a defined range, the synergistic effect of the two in relieving visual fatigue, such as anti-blue light, is more significant.

[0039] In some embodiments of the first embodiment, the nutritional composition is for oral use by humans, and the dosage of the neuraminic acid is 2-300 mg / day, preferably 7-300 mg / day (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 mg / day, or a range defined by any two of them), and the dosage of medium and long chain fatty acid triglycerides can be calculated based on the ratio of the two.

[0040] In some embodiments of the first embodiment, the nutritional composition is for oral use by humans, and its dosage is such that the dosage of the medium- and long-chain fatty acid triglycerides can be, for example, 0.1-30.0 g / day (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0 g / day, or a range defined by any two of them).

[0041] In a second embodiment, the improving vision may include preventing myopia, and wherein the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid may be 2: 1 to 200: 1. When the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is within the above range, there is a significant synergistic effect between nervonic acid and medium-chain fatty acid triglyceride in preventing myopia.

[0042] In some embodiments of the second embodiment, the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid may be 2: 1 to 80: 1. When the weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is within this range, the synergistic effect of nervonic acid and medium-chain fatty acid triglyceride in preventing myopia is more obvious.

[0043] In some embodiments of the second embodiment, the nutritional composition is for oral use by humans, and the dosage of the neuraminic acid is 2-300 mg / day, preferably 7-300 mg / day (for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 mg / day, or a range defined by any two of them), and the dosage of medium and long chain fatty acid triglycerides can be calculated based on the ratio of the two.

[0044] In some embodiments of the second embodiment, the nutritional composition is for oral use by humans, and its dosage is such that the dosage of the medium- and long-chain fatty acid triglycerides can be, for example, 0.1-30.0 g / day (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0 g / day, or a range defined by any two of them).

[0045] In the present application, the non-therapeutic purpose (non-medical therapeutic purpose) for improving vision is, for example, for preparing food for improving vision (such as functional food or health food).

[0046] In some embodiments, the improving vision is improving the vision of infants and / or children.

[0047] Furthermore, the present invention also relates to the use of a nutritional composition as defined herein for the preparation of a medicament for improving vision.

[0048] The present invention has no special requirements for the dosage form of the drug, and the dosage form commonly used in the art can be used. As an example, the drug of the present invention can be a solid preparation, such as powder, granules, tablets, capsules, drop pills, pills, etc.; a semi-solid preparation, such as an ointment, cream, eye ointment, gel, etc.; a liquid preparation, such as an oral liquid preparation, such as a syrup, mixture, suspension, emulsion, etc.

[0049] It is easy for those skilled in the art to understand that the drug may also include various pharmaceutically acceptable excipients according to different drug dosage forms and application scenarios. In addition, the drug of the present invention can be prepared by methods commonly used in the art, which will not be described in detail here.

[0050] Example

[0051] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0052] The sources and specifications of the raw materials used in the following examples are as follows: medium-chain fatty acid triglycerides: medium-chain fatty acid edible oil produced by Qingdao Haizhiyuan Life Science Technology Co., Ltd. (production batch number Y1505-22120101) was used, wherein the purity of medium-chain fatty acid triglycerides was 69±10% by weight; neuraminic acid: purchased from Fuheng Biology (production batch number FH20240120), the purity of neuraminic acid was 90±5% by weight; AB strain zebrafish: provided by the fish breeding center of Hangzhou Huante Biotechnology Co., Ltd.; coenzyme Q10: purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (production batch number K2211223); lumican-MO: purchased from Beijing Sizhengbai Biotechnology Co., Ltd. (production batch number 7-19Mar24A); zebrafish standard gene fragment: purchased from Beijing Sizhengbai Biotechnology Co., Ltd. (production batch number 31-10Jan24A-6-T); atropine sulfate monohydrate ( monohydrate): purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (production batch number I2111034); standard dilution water: prepared by Hangzhou Huante Biotechnology Co., Ltd., its main components are: 294.0 mg / L of dihydrate calcium chloride ( ), 123.3 mg / L magnesium sulfate heptahydrate ( ), 63.0 mg / L sodium bicarbonate ( ), 5.5 mg / L potassium chloride (KCl); calcium chloride dihydrate, magnesium sulfate heptahydrate: purchased from Shanghai MacLean Biochemical Technology Co., Ltd.; sodium bicarbonate: purchased from Sinopharm Chemical Reagent Co., Ltd.; and potassium chloride: purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.

[0053] In the following examples, AB strain zebrafish were used for animal experiments.

[0054] 1. Anti-blue light experiment

[0055] 1.1 Use of medium-chain triglycerides or neuraminic acid alone

[0056] Wild-type AB strain zebrafish 1 day after fertilization (1 dpf) were randomly selected. After that, after the zebrafish larvae broke through the membrane and hatched, some zebrafish were selected and irradiated with blue light using a blue light meter (50W, 450nm, China) for 7 hours a day for 4 consecutive days to damage the eyes of the zebrafish larvae in order to establish a zebrafish blue light eye damage model. Then, model zebrafish with good development status at 3 days after fertilization (3 dpf) were selected as model control group zebrafish and experimental group zebrafish, and zebrafish with good development status at 3 days after fertilization (3 dpf) were selected from zebrafish that had not been irradiated with blue light as normal control group.

[0057] The model control group, normal control group and experimental group zebrafish were randomly assigned to 6-well plates, with 30 zebrafish in each well. Figure 1 , Figure 2 The zebrafish were fed with the amounts of medium-chain fatty acid triglycerides and nervonic acid listed in the experiment at one time; the model control group and the normal control group were not fed with any medium-chain fatty acid triglycerides and nervonic acid. For the positive control group, the model control group was fed with 62.5 μg / mL of coenzyme Q10. The culture medium was not changed during the entire experiment.

[0058] After being kept at 28°C for 1 day, each group of zebrafish was stained with AO (acridine orange) in the dark for 30 minutes. Then, the stained zebrafish were washed 3 times with standard dilution water. Ten zebrafish were randomly selected from each group and placed under an electric focusing continuous zoom fluorescence microscope (AZ100, Nikon, Japan, magnification 160x) for photography. Afterwards, the photographs taken were analyzed using Image J software (Java1.8.0 172 (64-bit)), and the fluorescence intensity (pixel) of apoptotic cells in the eyes of zebrafish was collected. SPSS 26.0 software was used to perform statistical analysis on the collected fluorescence intensity data, and the statistical analysis results were expressed in the form of mean ± standard error (SE, Standard Error), where p < 0.05 indicated that the difference was statistically significant.

[0059] Figure 1 The photographs show the fluorescence intensity of apoptotic cells in the eyes of zebrafish in the normal control group, the model control group, the positive control group using coenzyme Q10, and the experimental groups using medium-chain triglycerides (MLCT) or neuraminic acid alone; Figure 2 The fluorescence intensity of apoptotic cells in the eyes of zebrafish in the normal control group, model control group, positive control group using coenzyme Q10, and experimental groups using medium- and long-chain fatty acid triglycerides or neuraminic acid alone, as well as the statistical analysis results compared with the model control group, are presented.

[0060] Combination Figure 1and Figure 2 It can be seen that the fluorescence intensity of the model control group increased significantly compared with the normal control group, indicating that blue light irradiation caused damage to the zebrafish's eyes, that is, the model was successfully established. In addition, compared with the model control group, the fluorescence intensity of the experimental groups fed with medium-chain fatty acid triglycerides or neuraminic acid was weaker, indicating that after feeding with medium-chain fatty acid triglycerides or neuraminic acid, the damage to the zebrafish's eyes caused by blue light was improved.

[0061] In addition, from Figure 1 and Figure 2 It can also be seen that as the feeding amount of medium-chain fatty acid triglycerides increased from 86μg / mL to 345μg / mL, the measured fluorescence intensity gradually weakened, indicating that the improvement effect of anti-blue light gradually increased, and when the feeding amount of medium-chain fatty acid triglycerides continued to increase from 345μg / mL to 690μg / mL, the fluorescence intensity hardly changed. This shows that when the feeding amount of medium-chain fatty acid triglycerides reached 345μg / mL, the improvement effect of anti-blue light reached a platform. Similarly, as the feeding amount of neuraminic acid increased from 113μg / mL to 225μg / mL, the improvement effect of anti-blue light gradually increased, and when the feeding amount continued to increase, the improvement effect of anti-blue light hardly changed.

[0062] 1.2 Combination of medium-chain triglycerides and neuraminic acid

[0063] MLCT and NA were combined in various ratios as shown in Table 1 below to prepare different nutritional compositions 1 to 8.

[0064] The zebrafish in the experimental group (different experimental groups were fed with different types and / or amounts of food, but the others were the same), the normal control group zebrafish, the model control group zebrafish, and the positive control group zebrafish were prepared according to the method in Section 1.1, except that during the feeding stage, the corresponding nutritional composition was fed according to the total nutrient concentration and ratio in Table 1.

[0065] Figure 3 Photos of the zebrafish fluorescence intensity of the normal control group, model control group, positive control group, and experimental groups (including Examples 1 to 8) are presented, and the experimental results are summarized in Table 1.

[0066] Table 1 Anti-blue light test results of nutritional composition

[0067]

[0068] Note: a The total concentration of the composition in Table 1 is the total concentration of pure medium- and long-chain fatty acid triglycerides and pure nervonic acid; b The p value is the result of significant difference analysis between each experimental group and the model control group.

[0069] Combining Table 1 and Figure 3 It can be seen that compared with the model control group, the fluorescence intensity of the apoptotic cells in the eyes of the zebrafish in Examples 1 to 8 was significantly reduced, indicating that the feeding of medium-chain fatty acid triglycerides (MLCT) and neuraminic acid has improved the effect of improving the blue light damage of the zebrafish eyes. In addition, by comparing the fluorescence intensity of apoptotic cells in the eyes of Examples 1 to 8 with the feeding of MLCT (345 μg / mL) alone and neuraminic acid (225 μg / mL) alone, it can be seen that when MLCT and neuraminic acid are fed at the same time, even if the total amount of feeding of the two is reduced, the fluorescence intensity of apoptotic cells in the eyes is still significantly reduced relative to the feeding of MLCT (345 μg / mL) alone and neuraminic acid (225 μg / mL) alone, which indicates that there is a synergistic effect between medium-chain fatty acid triglycerides and neuraminic acid in improving the blue light damage of zebrafish eyes and thus in alleviating visual fatigue (blue light easily causes visual fatigue).

[0070] Further, it can be seen from Examples 1 to 8 that, relative to Example 8 in which the weight ratio of medium-chain fatty acid triglycerides to neuraminic acid is 510.3:1 and the dosage is higher, Examples 1 to 7 in which the weight ratio of medium-chain fatty acid triglycerides to neuraminic acid (MLCT / NA) is 1.4:1 to 305.9:1 achieve lower fluorescence intensity of apoptotic cells in the eye, indicating that the synergistic effect in improving resistance to blue light damage is further enhanced; Examples 2 to 7 in which the weight ratio of MLCT / NA is 2.3:1 to 305.9:1 have reduced fluorescence intensity of apoptotic cells in the eye relative to other Examples (Example 1 and Example 8) outside this ratio range, indicating that the synergistic effect in improving resistance to blue light damage is further enhanced. The synergistic effect in improving resistance to blue light damage is further enhanced; the fluorescence intensity of apoptotic cells in the eyes of Examples 2 to 6 with an MLCT / NA weight ratio of 2.3:1 to 152.6:1 is reduced compared with other Examples (Example 1, Example 7 and Example 8) outside this ratio range, indicating that the synergistic effect in improving resistance to blue light damage is further enhanced; the fluorescence intensity of apoptotic cells in the eyes of Examples 2 to 5 with an MLCT / NA weight ratio of 2.3:1 to 75.9:1 is further reduced compared with other Examples (Example 1, and Examples 6 to 8) outside this ratio range, indicating that the synergistic effect in improving resistance to blue light damage is further enhanced.

[0071] 2. Myopia prevention experiment

[0072] 2.1 Use of medium-chain triglycerides or neuraminic acid alone

[0073] Wild-type AB strain zebrafish at the one-cell stage (0-15min after fertilization) were randomly selected and distributed in 6-well plates for experiments. The capacity of each well was 3mL, and there were 30 zebrafish in each well. Some zebrafish were selected as the normal control group; another part of the zebrafish was selected and injected with 2 nL (nanoliter) / tail of lumican-MO (zebrafish lumican gene fragment) to impair the vision of the zebrafish in order to establish a zebrafish myopia model; another part of the zebrafish was selected and subjected to the same treatment process as the model group, with a one-time injection of 2 nL / tail of the zebrafish standard gene fragment (i.e., the normal gene fragment, which does not affect the vision of the zebrafish) as the MO standard control group. This group was compared with the normal control group to determine that the myopia model was due to visual impairment induced by the inhibition of lumican gene expression. Then, for each experimental group, medium- and long-chain fatty acid triglycerides (MLCT) and neuraminic acid were adjusted according to the formula: Figure 4 , Figure 5 The model zebrafish were fed once with the amount listed in; no medium-chain fatty acid triglycerides and neuraminic acid were fed to the model control group, MO standard control group and normal control group; for the positive control group, 2500 μg / mL of atropine sulfate monohydrate was fed once to the model zebrafish. The culture medium was not changed during the entire experiment.

[0074] After feeding, keep at 28 ° C for 3 days. Then, 10 zebrafish were randomly selected from each group and placed under a dissecting microscope (SZX7, OLYMPUS, Japan, magnification 80x) for photography. Afterwards, the photos taken were analyzed using NIS-Elements D 3.20 software, and the zebrafish retinal pigment epithelium diameter / sclera diameter (D) was collected. The statistical analysis results of this index were used to evaluate the efficacy of the sample in preventing myopia. SPSS 26.0 software was used to perform statistical analysis on the collected fluorescence intensity data, and the statistical analysis results were expressed in the form of mean ± standard error, where p < 0.05 indicated that the difference was statistically significant.

[0075] Figure 4 The photographs show the retinal pigment epithelium diameter / sclera diameter of zebrafish in the normal control group, model control group, MO standard control group, positive control group using atropine, and experimental groups using medium-chain triglycerides (MLCT) or neuraminic acid alone; Figure 5 The retinal pigment epithelium diameter / sclera diameter of zebrafish in the normal control group, model control group, MO standard control group, positive control group using atropine, and experimental groups using medium- and long-chain fatty acid triglycerides or neuraminic acid alone, as well as the statistical analysis results compared with the model control group, were presented.

[0076] Combination Figure 4 and Figure 5It can be seen that compared with the normal control group, the retinal pigment epithelium diameter / sclera diameter of the model control group decreased significantly, indicating that feeding lumican-MO caused a decrease in the vision of zebrafish, that is, the modeling was successful.

[0077] In addition, compared with the model control group, the retinal pigment epithelium diameter / sclera diameter of the experimental group fed with medium-chain triglycerides (MLCT) or neuraminic acid was larger, indicating that the vision of zebrafish was improved after feeding with medium-chain triglycerides or neuraminic acid.

[0078] In addition, from Figure 4 and Figure 5 It can also be seen that as the feeding amount of medium-chain triglycerides (MLCT) increased from 86μg / mL to 345μg / mL, the measured retinal pigment epithelial diameter / scleral diameter gradually increased, indicating that the improvement effect on myopia gradually increased, and when the feeding amount of medium-chain triglycerides continued to increase from 345μg / mL to 690μg / mL, the retinal pigment epithelial diameter / scleral diameter change hardly changed. This shows that when the feeding amount of medium-chain triglycerides reaches 345μg / mL, the improvement effect on myopia reaches a plateau. Similarly, as the feeding amount of neuraminic acid increased from 113μg / mL to 225μg / mL, the improvement effect on myopia gradually increased, and when the feeding amount continued to increase, the improvement effect on myopia hardly changed.

[0079] 2.2 Combination of medium-chain triglycerides and neuraminic acid

[0080] Normal control group, MO standard control group, model control group, positive control group, and experimental group zebrafish were prepared as in Section 2.1 , except for the following: During the feeding phase, MLCT and NA were fed according to the total nutrient concentrations and MLCT / NA ratios in Table 2 .

[0081] Figure 6 Photos of the retinal pigment epithelium diameter / sclera diameter of zebrafish in the normal control group, MO standard control group, model control group, positive control group and experimental group are presented, and the experimental results are summarized in Table 2.

[0082] Table 2 Experimental results of the nutritional composition for preventing myopia

[0083]

[0084] Note: a The total concentration of the composition in Table 1 is the total concentration of pure medium- and long-chain fatty acid triglycerides and pure nervonic acid; b The p value is the result of significant difference analysis between each group and the model control group.

[0085] Combining Table 2 and Figure 6 It can be seen that compared with the model control group, the retinal pigment epithelium diameter / sclera diameter of the zebrafish in Examples 1 to 8 were significantly increased, indicating that feeding medium- and long-chain fatty acid triglycerides and neuraminic acid played a role in preventing myopia.

[0086] In addition, by comparing the retinal pigment epithelium diameter / sclera diameter in Examples 2 to 6 with the cases of feeding MLCT (345 µg / mL) alone and feeding neuraminic acid (225 µg / mL) alone, it can be seen that when medium-chain fatty acid triglycerides and neuraminic acid are fed simultaneously in an appropriate weight ratio, even if the total amount of the two is reduced, the retinal pigment epithelium diameter / sclera diameter is still significantly increased relative to the cases of feeding MLCT (345 µg / mL) alone and feeding neuraminic acid (225 µg / mL) alone, which indicates that there is a synergistic effect between medium-chain fatty acid triglycerides and neuraminic acid in preventing myopia.

[0087] Furthermore, Examples 2 to 5 with MLCT / NA weight ratios of 2.3:1 to 75.9:1 showed a significant increase in retinal pigment epithelium diameter / sclera diameter relative to other Examples (Example 1, and Examples 6 to 8) outside this ratio range, indicating that the synergistic effect in preventing vision is further enhanced.

[0088] The above description is only an exemplary embodiment of the present invention. It should be noted that, for those skilled in the art, without departing from the creative concept of the present invention, the present invention can also be improved, but these all belong to the protection scope of the present invention.

Claims

1. Use of a nutritional composition for the non-therapeutic purpose of improving vision, characterized in that The nutritional composition comprises: Medium and long chain fatty acid triglycerides; and Neural acid.

2. The use according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is 1:1 to 550:

1.

3. The use according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is 1:1 to 350:

1.

4. The use according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the nervonic acid is 2:1 to 200:

1.

5. The use according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the neuraminic acid is 2:1 to 80:

1.

6. The use according to any one of claims 1 to 5, characterized in that The nutritional composition is used in the form of a food comprising the same.

7. The use according to claim 6, characterized in that The food is infant food.

8. The use according to claim 6, characterized in that The food is selected from dairy products, candies, beverages, bread and biscuits.

9. The use according to claim 6, characterized in that The food is milk powder or fermented food.

10. The use according to claim 9, characterized in that The milk powder is infant formula milk powder.

11. The use according to claim 6, characterized in that The food further comprises one or more components selected from the following: raw cow milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blending oil, oligofructose, oligogalactose, nucleotides, choline, vitamins, minerals, docosahexaenoic acid and taurine.

12. The use according to any one of claims 1 to 5, characterized in that The improving vision includes alleviating visual fatigue and optionally further includes preventing myopia.

13. The use according to claim 12, characterized in that The relief of visual fatigue includes anti-blue light.

14. The use according to claim 4 or 5, characterized in that The improving vision includes preventing myopia.

15. The use according to claim 6, characterized in that The food is a health food.

16. Use of a nutritional composition as defined in any one of claims 1 to 15 for the preparation of a medicament for improving vision.

Images